South Africa’s Aspen posts 6 pct rise in H1 profit

South African drugmaker Aspen Pharmacare Holdings Ltd reported a 6 percent rise in first-half profit on Thursday, helped by the results of a recently acquired portfolio of medicines from AstraZeneca.

Aspen, the biggest generic drugmaker in the southern hemisphere, said normalised headline earnings per share rose to 692 cents in the six months ended December 2016, from 656 cents a year earlier.

Headline EPS is the main profit measure in South Africa and strips out certain one-off items.

Aspen said the results were largely boosted by the $770 million acquisition of marketing rights to a portfolio of anaesthetics from AstraZeneca in September last year.

(Reporting by Tiisetso Motsoeneng; Editing by Subhranshu Sahu)

 

Partner Content

Star Quality Speaker Line-Up at Africa Tech Festival 2020

Acknowledged as the world’s largest Africa-focused digital infrastructure and emerging tech event, the Africa Tech Festival has always attracted a stellar line-up of critical thinkers, analysts, futurists, keynote and inspirational speakers. 2020 will more than deliver on that reputation, with a stimulating array of visionary industry presenters, raconteurs and even some sporting greats.

Leveling the playing field for female entrepreneurs in Africa

By Olga Arara-Kimani, Regional Head, Corporate Affairs and Brand & Marketing Introduction Mobilising support for female...

Smart Mobility: Gautrain the sustainable way of travel!

The theme for October Transport Month 2020 is Smart Mobility.  Smart Mobility is an innovative way of getting around. it is the...

Newsletter

Sign up for free newsletters and get more CNBC AFRICA delivered to your inbox